Xpert MTB/XDR 检测异烟肼、氟喹诺酮、乙硫异烟胺、阿米卡星、卡那霉素和卷曲霉素耐药性的横断面多中心诊断准确性研究
该前瞻性研究在印度、摩尔多瓦和南非四个中心纳入有耐药风险的肺结核症状者,以表型药敏试验和全基因组测序复合参考标准评估 Xpert MTB/XDR Reflex 检测的准确性。
要点
- Xpert MTB/XDR 检测异烟肼和氟喹诺酮耐药敏感性均为94%,特异性98-100%。
- 对乙硫异烟胺、阿米卡星、卡那霉素和卷曲霉素敏感性较低(54%-86%)。
核心结论
- Xpert MTB/XDR 检测表现出高诊断准确性,满足 WHO 下一代药敏检测的最低目标产品特性标准。
研究设计与样本
- 前瞻性横断面多中心诊断准确性研究,2019年7月31日至2020年3月21日在印度(新德里和孟买)、摩尔多瓦和南非四个中心纳入有耐药风险的肺结核症状者。
- 710 名参与者中 611 名(86%)具有 Xpert MTB/XDR 和参考标准结果并纳入分析。
- 参考标准为表型药敏试验和全基因组测序的复合标准。
主要发现
- Xpert MTB/XDR 检测耐药敏感性:异烟肼 94%(460/488,95%CI 92-96),氟喹诺酮 94%(222/235,95%CI 90-96%)。
- 乙硫异烟胺敏感性 54%(178/328,95%CI 50-61),阿米卡星 73%(60/82,95%CI 62-81)。
- 卡那霉素敏感性 86%(181/210,95%CI 81-91),卷曲霉素 61%(53/87,95%CI 49-70)。
- 所有药物的特异性为 98-100%,性能与线性探针检测等效。
关键数值与推荐
- 敏感性阈值:异烟肼和氟喹诺酮均为94%,乙硫异烟胺54%,阿米卡星73%,卡那霉素86%,卷曲霉素61%。
- 特异性范围为98-100%。
临床怎么用
- Xpert MTB/XDR 可作为反射检测快速诊断耐药结核,尤其对异烟肼和氟喹诺酮耐药准确性高。
- 对乙硫异烟胺、阿米卡星、卡那霉素和卷曲霉素耐药检测敏感性较低,临床解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The WHO End TB Strategy requires drug susceptibility testing and treatment of all people with tuberculosis, but second-line diagnostic testing with line-probe assays needs to be done in experienced laboratories with advanced infrastructure. Fewer than half of people with drug-resistant tuberculosis receive appropriate treatment. We assessed the diagnostic accuracy of the rapid Xpert MTB/XDR automated molecular assay (Cepheid, Sunnyvale, CA, USA) to overcome these limitations. METHODS: We did a prospective study involving individuals presenting with pulmonary tuberculosis symptoms and at least one risk factor for drug resistance in four sites in India (New Delhi and Mumbai), Moldova, and South Africa between July 31, 2019, and March 21, 2020. The Xpert MTB/XDR assay was used as a reflex test to detect resistance to isoniazid, fluoroquinolones, ethionamide, amikacin, kanamycin, and capreomycin in adults with positive results for Mycobacterium tuberculosis complex on Xpert MTB/RIF or Ultra (Cepheid). Diagnostic performance was assessed against a composite reference standard of phenotypic drug-susceptibility testing and whole-genome sequencing. This study is registered with ClinicalTrials.gov, number NCT03728725. FINDINGS: Of 710 participants, 611 (86%) had results from both Xpert MTB/XDR and the reference standard for any drug and were included in analysis. Sensitivity for Xpert MTB/XDR detection of resistance was 94% (460 of 488, 95% CI 92-96) for isoniazid, 94% (222 of 235, 90-96%) for fluoroquinolones, 54% (178 of 328, 50-61) for ethionamide, 73% (60 of 82, 62-81) for amikacin, 86% (181 of 210, 81-91) for kanamycin, and 61% (53 of 87, 49-70) for capreomycin. Specificity was 98-100% for all drugs. Performance was equivalent to that of line-probe assays. The non-determinate rate of Xpert MTB/XDR (ie, invalid M tuberculosis complex detection) was 2·96%. INTERPRETATION: The Xpert MTB/XDR assay showed high diagnostic accuracy and met WHO's minimum target product profile criteria for a next-generation drug susceptibility test. The assay has the potential to diagnose drug-resistant tuberculosis rapidly and accurately and enable optimum treatment. FUNDING: German Federal Ministry of Education and Research through KfW, Dutch Ministry of Foreign Affairs, and Australian Department of Foreign Affairs and Trade.
引用
- Penn-Nicholson A, Georghiou SB, Ciobanu N, et al. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2021. PMID: 34627496. doi:10.1016/S1473-3099(21)00452-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。